Search bioRxiv⌕ Search

Biology subjects

Yeang, C.-H.

Publications and source records attributed to Yeang, C.-H..

5 recordsLinked to original sources

Deep Mediation Analysis for Multimodal Genotype-Imaging Associations with Disease Phenotypes

Both genotype and imaging data carry entangled information about the phenotypes. Associations between genotypes and phenotypes can be manifested or absent on biomedical images. While there are abundant multimodal association studies integrating genotype and imaging data, few of them disentangle their direct and indirect effects in associations. We propose GIF (Genotype-Image-Phenotype), a novel modeling framework to predict phenotypes by genotype and imaging data with a mediation structure of these three sets of variables. GIF constitutes a backbone of mediation path genotype[->]image[->]phenotype, and direct genotype[->]phenotype and image[->]phenotype paths capturing the additional direct associations not explained by the mediation model. To implement the mediation model with a convolutional neural network (CNN), we constructed a CNN to predict genotypes with images and then employed the joint embedding vectors of the CNN to predict phenotypes. The direct links were sequentially augmented to the mediation model to further improve prediction accuracy. We validated GIF on three datasets: (1) a synthetic polygon dataset where the presence or absence of a polygon specie indicates a genotype and selected combinations of multiple polygon species indicate phenotypes, (2) the PASCAL VOL dataset of object detection and action recognition, where the presence or absence of an object class indicates a genotype and the presence or absence of an action class indicates a phenotype, (3) the ADNI dataset of Alzheimers disease diagnosis comprising the genotype and imaging data of subjects with three cognitive states. GIF prediction outcomes on the ADNI data indicate the associations between genotypes and phenotypes are primarily mediated by image features, and images provide additional information about phenotypes which is not attributed to genotype variations.

bioinformatics↗

Probability Distribution for Rare Neutral Mutations in Cancers and Application to Dynamic Precision Medicine of Cancer

Cancers exhibit substantial genetic diversity between individual cells. Previous work shows greater overall diversity that also increases more quickly during a patients clinical course than heretofore expected. Rare subclones will harbor pre-existing resistance to any single agent and may cause medium to late term relapse, which may evolve further variants that have simultaneous resistance to non-cross resistant therapies. In this work, we present a probability distribution function (PDF) of the variant allele fraction (VAF), or prevalence, of a rare subclone, derived from previous evolutionary theory. We show that current clinical sequencing protocols fail to detect the vast majority of these rare subclones and that by the time of detection, simultaneous multiple resistance may already evolve. We apply the PDF to simulation of dynamic precision medicine (DPM), an evolutionary guided precision medicine paradigm that attempts to proactively eliminate singly-resistant subclones before they evolve multiple resistance, with significant potential to extend survival. We show the simulated benefit of DPM with perfect information is hampered by an inability to detect rare subclones if they are assumed to be absent when undetectable. However, the DPM benefit is restored if the PDF is used to calculate the likelihood of the subclone being present below the level of detection and incorporated into the DPM simulation and therapy recommendations in a probabilistic fashion. Two other common statistical distributions are less effective. This theoretical advance facilitates DPM and potentially other evolutionary guided approaches to precision cancer medicine in spite of the limitations of clinical sequencing. Significance StatementCancers contain many cells, each genetically unique. These variations can include pre-existing resistance to therapy, enabling relapse. DNA sequencing cannot detect minority cellular populations (subclones) below a certain size, by which time they may have already evolved simultaneous resistance to multiple therapies. We present a mathematical approach that assigns a risk that a subclone is present, and at what prevalence in the cellular population, even when undetected. We simulate applying this approach to dynamic precision medicine (DPM), which attempts to proactively eliminate singly resistant cells before they become resistant to multiple therapies. Using this probability distribution, we can retain the benefit of DPM even when most rare subclones are undetectable, in contrast to just assuming undetected subclones are absent.

systems biology↗

Personalized cancer treatment strategies incorporating irreversible and reversible drug resistance mechanisms

Despite advances in targeted cancer therapy, the promise of precision medicine has been limited by resistance to these treatments. In this study, we propose a mathematical modelling framework incorporating cellular heterogeneity, genetic evolutionary dynamics, and non-genetic plasticity, accounting for both irreversible and reversible drug resistance. Previously we proposed Dynamic Precision Medicine (DPM), a personalized treatment strategy that designed individualized treatment sequences by simulations of irreversible genetic evolutionary dynamics in a heterogeneous tumor. Here we apply DPM to the joint model of reversible and irreversible drug resistance mechanisms, analyze the simulation results and compare the efficacy of various treatment strategies. The results indicate that this enhanced version of DPM results in superior patient outcomes compared with current personalized medicine treatment approaches. Our results provide insights into cancer treatment strategies for heterogeneous tumors with genetic evolutionary dynamics and non-genetic cellular plasticity, potentially leading to improvements in survival time for cancer patients.

systems biology↗

Population histories of the United States revealed through fine-scale migration and haplotype analysis

The population of the United States is shaped by centuries of migration, isolation, growth, and admixture between ancestors of global origins. Here, we assemble a comprehensive view of recent population history by studying the ancestry and population structure of over 32,000 individuals in the US using genetic, ancestral birth origin, and geographic data from the National Geographic Genographic Project. We identify migration routes and barriers that reflect historical demographic events. We also uncover the spatial patterns of relatedness in subpopulations through the combination of haplotype clustering, ancestral birth origin analysis, and local ancestry inference. Examples of these patterns include substantial substructure and heterogeneity in Hispanics/Latinos, isolation-by-distance in African Americans, elevated levels of relatedness and homozygosity in Asian immigrants, and fine-scale structure in European descents. Taken together, our results provide detailed insights into the genetic structure and demographic history of the diverse US population.

genetics↗

Modelling bistable tumour population dynamics to design effective treatment strategies

Despite recent advances in targeted drugs and immunotherapy, cancer remains \"the emperor of all maladies\" due to inevitable emergence of resistance. Drug resistance is thought to be driven by mutations and/or dynamic plasticity that deregulate pathway activities and regulatory programs of a highly heterogeneous tumour. In this study, we propose a modelling framework to simulate population dynamics of heterogeneous tumour cells with reversible drug resistance. Drug sensitivity of a tumour cell is determined by its internal states, which are demarcated by coordinated activities of multiple interconnected oncogenic pathways. Transitions between cellular states depend on the effects of targeted drugs and regulatory relations between the pathways. Under this framework, we build a simple model to capture drug resistance characteristics of BRAF-mutant melanoma, where two cell states are described by two mutually inhibitory - main and alternative - pathways. We assume that cells with an activated main pathway are proliferative yet sensitive to the BRAF inhibitor, and cells with an activated alternative pathway are quiescent but resistant to the drug. We describe a dynamical process of tumour growth under various drug regimens using the explicit solution of mean-field equations. Based on these solutions, we compare efficacy of three treatment strategies: static treatments with continuous and constant dosages, periodic treatments with regular intermittent phases and drug holidays, and treatments derived from optimal control theory (OCT). Based on these analysis, periodic treatments outperform static treatments with a considerable margin, while treatments based on OCT outperform the best periodic treatment. Our results provide insights regarding optimal cancer treatment modalities for heterogeneous tumours, and may guide the development of optimal therapeutic strategies to circumvent drug resistance and due to tumour plasticity.

cancer biology↗